Loading
Life sciences · Observational Study
ClinicalTrials.gov · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07833267). This is a study registration, not published results. Lead sponsor: Xuanwu Hospital, Beijing. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 3000 participants (ESTIMATED). Conditions: Neurodegenerative Disease, Dementia, Alzheimer's Disease, Parkinson's Disease, Mood Disorders, Depression, Anxiety Disorder, Bipolar Disorder, Behavior Disorders. Primary outcome measures: Mini-Mental State Examination (MMSE) , Baseline, 1 years, 2years，3years and 4years; Montreal Cognitive Assessment , Baseline, 1 years, 2years，3years and 4years; Hamilton Depression Rating Scale , Baseline, 1 years, 2years，3years and 4years; Hamilton Anxiety Rating Scale , Baseline, 1 years, 2years，3years and 4years; Neuropsychiatric Inventory , Baseline, 1 years, 2years，3years and 4years. Brief summary: This is a prospective cohort study of patients with cognitive impairment mood disorders and behavioral disorders. Comprehensive baseline and longitudinal follow-up assessments include clinical and epidemiological data, cognitive function and neuropsychological assessments, laboratory measurements, and neuroimaging data, along with the collection of blood, urine, feces, and cerebrospinal fluid for biobanking. Multi-omics, multidimensional cognitive assessments, and multimodal neuroimaging data are integrated using statistical analyses to establish a comprehensive clinical database and biobank. The study aims to identify risk factors, elucidate mechanisms underlying the comorbidity of cognitive impairment and mood disorders, discover multimodal biomarkers, and improve early screening, risk prediction, and diagnosis